Sugi Predict

Sugi Predict / Compounds / SCHEMBL3108600

SCHEMBL3108600

SCHEMBL3108600

COC(=O)C=Cc1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.54
▸ TTR P02766 1/20 0.53
▸ APP P05067 1/20 0.53
▸ PTGS2 P35354 3/20 0.52
▸ KDM4E B2RXH2 3/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ GAA P10253 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ SIRT2 Q8IXJ6 1/20 0.51
▸ SIRT1 Q96EB6 1/20 0.51
▸ P4HB P07237 2/20 0.50
▸ ATM Q13315 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ MAOB P27338 1/20 0.50
▸ EPHX2 P34913 1/20 0.49
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3108598 1.00 BCHE (0.54) BCHETTRAPPPTGS2KDM4E
SCHEMBL1410896 0.88 P4HB (0.57) BCHETTRAPPKDM4EGAA
SCHEMBL1410893 0.88 P4HB (0.57) BCHETTRAPPKDM4EGAA
SCHEMBL31021318 0.88 P4HB (0.57) BCHETTRAPPKDM4EGAA
SCHEMBL6369117 0.85 BCHE (0.69) BCHEKMT2AMEN1P4HBMAOB
SCHEMBL18098004 0.84 P4HB (0.68) BCHETTRAPPKDM4EKMT2A
SCHEMBL4732774 0.84 PTGS2 (0.73) TTRPTGS2MAOBCA12CA1
SCHEMBL69618 0.84 TTR (0.66) TTRAPPKDM4EKMT2AGAA
SCHEMBL6171570 0.83 PARP1 (0.59) BCHETTRAPPKDM4EKMT2A
SCHEMBL6171568 0.83 PARP1 (0.59) BCHETTRAPPKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200385340-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LTD (AU) 2020-12-10 — — US disclosed
US-10683263-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2020-06-16 — — US disclosed
EP-2826770-B1 ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY BIOTRON LTD (AU) 2018-09-12 — — EP disclosed
US-20170362170-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LTD (AU) 2017-12-21 — — US disclosed
US-20160376231-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2016-12-29 — — US disclosed
EP-2659885-B1 Hepatitis C Antiviral Compositions and Methods BIOTRON LTD (AU) 2016-11-09 — — EP disclosed
US-9440926-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2016-09-13 — — US disclosed
CN-101827589-B The compositions of anti-hepatitis c virus and method 拜伊特朗有限公司 2016-08-17 — — CN disclosed
EP-2194976-B1 Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine BIOTRON LTD (AU) 2015-12-09 — — EP disclosed
CN-103274970-B Antiviral compounds and methods BIOTRON LTD 2015-02-25 — — CN disclosed
CN-103274970-A Antiviral compounds and methods BIOTRON LTD 2013-09-04 — — CN disclosed
CN-101208297-B Antiviral compounds and methods BIOTRON LTD 2013-04-24 — — CN disclosed
US-20100254942-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED (AU) 2010-10-07 — — US disclosed
CN-101827589-A Hepatitis c antiviral compositions and methods BIOTROM LTD 2010-09-08 — — CN disclosed
EP-2194976-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS Biotron Limited (AU) 2010-06-16 — — EP disclosed
US-20090099239-A1 Antiviral Compounds and Methods BIOTRON LIMITED (AU) 2009-04-16 — — US disclosed
WO-2009018609-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTROM LIMITED (AU) 2009-02-12 — — WO disclosed
CN-101208297-A Antiviral compounds and methods BIOTRON LTD (AU) 2008-06-25 — — CN disclosed
EP-1902017-A1 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2008-03-26 — — EP disclosed
WO-2006135978-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2006-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100254942-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 BCHE 832/4885TTR 2971/4885APP 4565/4885
US-10683263-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 BCHE 1598/4885TTR 3733/4885APP 4353/4885
US-20170362170-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 BCHE 832/4885TTR 2971/4885APP 4565/4885
US-20090099239-A1 Antiviral Compounds and Methods MAVS, ZC3HAV1, EIF2AK2 BCHE 1598/4885TTR 3733/4885APP 4353/4885
US-20160376231-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 BCHE 1598/4885TTR 3733/4885APP 4353/4885
US-20200385340-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 BCHE 832/4885TTR 2971/4885APP 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.